The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 April 2006, www.theannals.com, DOI 10.1345/aph.1G471.
 The Annals of Pharmacotherapy: Vol. 40, No. 5, pp. 931-934. DOI 10.1345/aph.1G471
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shields, K. M
Right arrow Articles by Hrometz, S. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shields, K. M
Right arrow Articles by Hrometz, S. L

DRUG INFORMATION ROUNDS

Use of Sildenafil for Female Sexual Dysfunction

Kelly M Shields, PharmD

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University, Ada, OH

Sandra L Hrometz, PhD

Associate Professor of Pharmacology, Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University

Reprints: Dr. Shields, Department of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810-1078, fax 419/772-2289, k-shields{at}onu.edu

OBJECTIVE: To review the pathophysiology of female sexual dysfunction (FSD) and the literature regarding the use of sildenafil in its treatment.

DATA SOURCES: Literature was accessed through MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), EMBASE (1966-April 2006), and bibliographies of pertinent articles. Search terms included female sexual dysfunction; sexual dysfunction, psychological; phosphodiesterase inhibitors; and sildenafil.

DATA SYNTHESIS: The lack of a clear understanding of FSD contributes to the limited treatment options available. Studies regarding the safety and efficacy of the phosphodiesterase 5 inhibitor sildenafil in the management of FSD were evaluated. Many trials have been of poor quality, making clinical application of their results difficult. The current literature does not show sildenafil to be an effective treatment option for FSD.

CONCLUSIONS: Treatment of FSD should include both physical and psychological components. Based on the limited data available, it appears that sildenafil, while well tolerated, offers little or no benefit to most patients with FSD.

Key Words: female sexual dysfunction, phosphodiesterase inhibitors, sildenafil

Published Online, April 18, 2006. www.theannals.com, DOI 10.1345/aph.1G471


This article has been cited by other articles:


Home page
 The Obstetrician and GynaecologistHome page
C. Coulson and T. Crowley
Current thoughts on psychosexual disorders in women
Obstet Gynaecol (Lond), October 1, 2007; 9(4): 217 - 222.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.